ProQR Therapeutics N.V. (PRQR) shareholders
Close on Nov 17, 2026Market cap $121.17MP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| ELI LILLY & Co | 21,995,880 | 15.60% | 13G (passive) amendment | Jun 26, 2026 |
| Van Herk Investments THI B.V. Joint filing with Van Herk Investments B.V. (14.60%), Van Herk Private Equity Investments B.V. (14.60%) and 6 more | 15,384,250 | 14.60% | 13D (active) amendment | Jun 2, 2026 |
| Adrianus van Herk Joint filing with Van Herk Investments B.V. (10.90%), Van Herk Investments THI B.V. (10.90%) and 6 more | 15,384,250 | 10.90% | 13D (active) amendment | Jun 26, 2026 |
| Onroerend Goed Beheer- en Beleggingsmaatschappij A. van Herk B.V. Joint filing with Van Herk Investments B.V. (10.90%), Van Herk Investments THI B.V. (10.90%) and 6 more | 15,384,250 | 10.90% | 13D (active) amendment | Jul 27, 2026 |
| Stichting Administratiekantoor Penulata Joint filing with Van Herk Investments B.V. (14.60%), Van Herk Investments THI B.V. (14.60%) and 6 more | 15,384,250 | 14.60% | 13D (active) amendment | Feb 5, 2026 |
| A. van Herk Holding B.V. Joint filing with Van Herk Investments B.V. (13.60%), Van Herk Investments THI B.V. (13.60%) and 6 more | 14,329,690 | 13.60% | 13D (active) amendment | Sep 29, 2025 |
| Adage Capital Management, L.P. Joint filing with Robert Atchinson (9.30%), Phillip Gross (9.30%) | 9,602,280 | 9.30% | 13G (passive) | Dec 31, 2024 |
| Aberdeen Group plc Joint filing with abrdn Inc. (6.33%) | 8,932,507 | 6.33% | 13G (passive) | Jun 30, 2026 |
| Phillip Gross Joint filing with Adage Capital Management, L.P. (7.70%), Robert Atchinson (7.70%) | 8,102,098 | 7.70% | 13G (passive) amendment | Mar 31, 2025 |
| Robert Atchinson Joint filing with Adage Capital Management, L.P. (6.27%), Phillip Gross (6.27%) | 6,601,938 | 6.27% | 13G (passive) amendment | Jun 30, 2025 |
| Patrick Johan Hendrik Krol | 5,528,862 | 5.20% | 13G (passive) amendment | Jul 15, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of PRQR | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Adage Capital Partners Gp, L.L.C. | 9,015,897 | 8.56% | $16.77M | +2,762,430 | 0.02% |
| abrdn plc | 8,932,507 | 8.48% | $16.61M | +5,615,542 | 0.02% |
| Affinity Asset Advisors, LLC | 5,543,936 | 5.26% | $10.31M | +3,089,658 | 0.47% |
| Privium Fund Management B.V. | 5,520,024 | 5.24% | $10.27M | +52,875 | 1.89% |
| Ikarian Capital, LLC | 3,425,930 | 3.25% | $6.37M | +1,933,701 | 0.69% |
| Woodline Partners LP | 3,277,143 | 3.11% | $6.10M | New | 0.02% |
| Heights Capital Management, Inc | 2,762,430 | 2.62% | $5.14M | New | 1.19% |
| Morgan Stanley | 1,767,215 | 1.68% | $3.29M | +467,440 | 0.00% |
| Sphera Funds Management Ltd. | 1,757,458 | 1.67% | $3.27M | New | 0.43% |
| Kynam Capital Management, LP | 1,566,317 | 1.49% | $2.91M | – | 0.16% |
| DAFNA Capital Management LLC | 1,530,361 | 1.45% | $2.85M | −37,200 | 0.54% |
| Squadron Capital Management LLC | 1,511,496 | 1.43% | $2.81M | New | 0.87% |
| 683 Capital Management, LLC | 1,393,067 | 1.32% | $2.59M | New | 0.13% |
| Citadel Advisors LLC | 1,184,314 | 1.12% | $2.20M | +480,991 | 0.00% |
| Platinum Investment Management Ltd | 1,159,428 | 1.10% | $2.16M | −76,086 | 0.53% |
| Two Sigma Investments, LP | 1,138,715 | 1.08% | $2.12M | +219,858 | 0.00% |
| Eversept Partners, LP | 1,022,265 | 0.97% | $1.90M | New | 0.10% |
| Boothbay Fund Management, LLC | 948,736 | 0.90% | $1.76M | +593,453 | 0.02% |
| Diadema Partners LP | 926,016 | 0.88% | $1.72M | +745,933 | 0.22% |
| UBS Group AG | 639,243 | 0.61% | $1.19M | +333,979 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 70 | 61M | 57.6% | 12 / 25 | 11 / 11 | 30M | 4M |
| Q1 2026 | 69 | 35M | 33.3% | 10 / 14 | 16 / 6 | 1M | 3M |
| Q4 2025 | 65 | 37M | 35.3% | 10 / 23 | 10 / 8 | 5M | 5M |
| Q3 2025 | 64 | 38M | 35.6% | 8 / 14 | 12 / 6 | 2M | 5M |
| Q2 2025 | 62 | 41M | 38.5% | 4 / 17 | 20 / 7 | 3M | 4M |
| Q1 2025 | 65 | 41M | 39.2% | 7 / 18 | 19 / 19 | 4M | 7M |
| Q4 2024 | 77 | 44M | 42.2% | 39 / 17 | 6 / 8 | 32M | 4M |
| Q3 2024 | 47 | 17M | 16.6% | 5 / 9 | 15 / 5 | 1M | 1M |
| Q2 2024 | 48 | 17M | 16.4% | 3 / 4 | 18 / 3 | 1M | 1M |
| Q1 2024 | 49 | 18M | 16.6% | 4 / 10 | 15 / 2 | 0M | 1M |
| Q4 2023 | 47 | 19M | 17.6% | 6 / 6 | 12 / 5 | 1M | 1M |
| Q3 2023 | 46 | 19M | 17.8% | 4 / 8 | 10 / 9 | 0M | 3M |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Boer Daniel Anton de | Chief Executive Officer, Director | 500,000 | 0.47% | Aug 3, 2026 |
| Gerardus Johannes Platenburg | Chief Scientific Officer, Director | 824,388 | 0.78% | Mar 18, 2026 |
| Dennis Hom | Chief Financial Officer | – | – | Mar 18, 2026 |
| Bart Filius | Director | 300,000 | 0.28% | Jul 21, 2026 |
| Gylvin Lykke Hinsch | Director | – | – | Jun 30, 2026 |
| Alison Frances Lawton | Director | – | – | Mar 18, 2026 |
| Martin Alexander Maier | Director | – | – | Mar 18, 2026 |
| Theresa Heggie | Director | 43,623 | 0.04% | Mar 18, 2026 |
| Domenico Valerio | Director | 725,692 | 0.69% | Mar 18, 2026 |
| Begona Carreno-Gomez | Director | – | – | Mar 18, 2026 |
| James Samuel Shannon | Director | 61,538 | 0.06% | Mar 18, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Boer Daniel Anton de Chief Executive Officer, Director | Jul 31, 2026 | Buy | +200,000 | $1.77 | $354.00K | 500,000 |
| Bart Filius Director | Jul 17, 2026 | Buy | +150,000 | $1.72 | $258.00K | 300,000 |
| Boer Daniel Anton de Chief Executive Officer, Director | Jul 9, 2026 | Buy | +150,000 | $1.74 | $261.00K | 300,000 |
| Boer Daniel Anton de Chief Executive Officer, Director | Jul 7, 2026 | Buy | +150,000 | $1.59 | $238.50K | 150,000 |
| Bart Filius Director | Jun 26, 2026 | Buy | +150,000 | $1.54 | $231.00K | 150,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of ProQR Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 10,723 shares on Sep 17, 2026 over the last 90 days.
See a number that looks wrong?